Synapse - Vincent Miller

Results (270)

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

Journal Article

Clarke, J. L.; Pao, W.; Wu, N.; Miller, V.; Lassman, A. B.
Journal of Neuro-Oncology (2010)

Fulltext@MSK | Save

Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): A preliminary report

Meeting Abstract

Yang, C.; Hirsh, V.; Cadranel, J.; Chen, Y.; Park, K.; Kim, S.; Chao, T.; Oberdick, M.; Shahidi, M.; Miller, V.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2)

Meeting Abstract

Shih, J.; Yang, C.; Su, W.; Hsia, T.; Tsai, C.; Chen, Y.; Chang, H.; Terlizzi, E.; Shahidi, M.; Miller, V. A.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Phase II study of induction and adjuvant bevacizumab in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) receiving induction docetaxel and cisplatin

Meeting Abstract

Price, K.; Kris, M. G.; Rusch, V.; Finley, D. J.; Azzoli, C. G.; Downey, R. J.; Bains, M. S.; Miller, V. A.; Rizk, N.; Rizvi, N. A.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations

Meeting Abstract

Janjigian, Y. Y.; Park, B. J.; Kris, M. G.; Miller, V. A.; Riely, G. J.; Zheng, J.; Dycoco, J. P.; Shen, R.; Azzoli, C. G.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations

Meeting Abstract

Johnson, M. L.; Rizvi, N. A.; Ginsberg, M. S.; Miller, V. A.; Kris, M. G.; Pao, W.; Riely, G. J.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)

Meeting Abstract

Arcila, M. E.; Riely, G. J.; Zakowski, M. F.; Kris, M. G.; Ladanyi, M.; Pao, W.; Miller, V. A.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

Meeting Abstract

Miller, V. A.; O'Connor, P.; Soh, C.; Kabbinavar, F.; for the ATLAS Investigators
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Reflex testing of lung adenocarcinomas for EGFR and KRAS mutations: The initial Memorial Sloan-Kettering Cancer Center (MSKCC) experience

Meeting Abstract

Zakowski, M. F.; Ladanyi, M.; Rekhtman, N.; Park, B.; Finley, D.; Azzoli, C.; Kris, M. G.; Rusch, V.; Miller, V.; Riely, G.
Journal of Thoracic Oncology (2009)

Fulltext@MSK | Save

BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaive patients with adenocarcinoma of the lung and activating EGFR mutations

Meeting Abstract

Yang, C. H.; Shih, J. Y.; Su, W. C.; Hsia, T. C.; Ho, C. L.; Dudek, A. Z.; Terlizzi, E.; Zhao, Y. H. M.; Shahidi, M.; Miller, V. A.
Journal of Thoracic Oncology (2009)

Fulltext@MSK | Save